Anthrax VaccineThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7

333 records returned

Milestone biodefense publication by Elsevier journal VaccineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Elsevier) Last week during the Vaccines for Biothreats and Emerging and Neglected Diseases Symposium in Galveston Texas, the Elsevier journal Vaccine released a supplement dedicated to vaccines for biodefense. This publication provides a comprehensive, state-of-the-art overview on vaccines that have been developed against a diverse group of human and veterinary pathogens, including Bacillus anthracis, smallpox and blue tongue. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 19, 2009 Category: Global & Universal Source Type: news

Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide LicensingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Human Anthrax Vaccine Program must be stopped. Scott Miller and Company has completed the feature film "A Call to Arms:2009 Edition" and the one-hour television documentary "Fatal Immunity: The Human Anthrax Vaccine Story" to inform the public about the clear and present danger of top secret government science turned into for-profit human anthrax vaccines with no accountability to its victims. It is available for world-wide licensing by motion picture and television distributors and exhibitors. (PRWeb Nov 4, 2009) Read the full story at http://www.prweb.com/releases/scottmillerandco/documentaryp...
Source: PRWeb: Medical Pharmaceuticals - November 6, 2009 Category: Pharmaceuticals Source Type: news

Human Anthrax Vaccines - A Call To ArmsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Human Anthrax Vaccine Program must be stopped. Scott Miller and Company has completed the feature film "A Call to Arms:2009 Edition" and the one-hour television documentary "Fatal Immunity: The Human Anthrax Vaccine Story" to inform the public about the clear and present danger of top secret government science turned into for-profit human anthrax vaccines with no accountability to its victims. It is available for world-wide licensing by motion picture and television distributors and exhibitors. (Source: Disabled World)
Source: Disabled World - November 5, 2009 Category: Disability Tags: Books and Publications Source Type: info

BioThrax (Anthrax Vaccine Adsorbed Emergent BioSolutions) - updated on RxListEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
BioThrax (Anthrax Vaccine Adsorbed Emergent BioSolutions) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 28, 2009 Category: Drugs & Pharmacology Source Type: consumer

Questions raised about Human Genome Science's anthrax vaccineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A report prepared for a Food and Drug Administration panel scheduled to consider approval of Human Genome Sciences Inc.’s experimental anthrax drug questions whether it works better in humans than existing treatments. (HGSI) (Source: bizjournals.com Health Care:Health Insurance headlines)
Source: bizjournals.com Health Care:Health Insurance headlines - October 23, 2009 Category: American Health Source Type: journals

Questions raised about Human Genome Science's anthrax vaccineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A report prepared for a Food and Drug Administration panel scheduled to consider approval of Human Genome Sciences Inc.’s experimental anthrax drug questions whether it works better in humans than existing treatments. (HGSI) (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 23, 2009 Category: Biotechnology Source Type: journals

What is the Appropriate Treatment for a Pedal Puncture Wound?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Discussion Ciprofloxacin and other fluoroquinolones have demonstrated cartilage and joint toxicity when administered to immature laboratory animals. Therefore health care providers have been reluctant to use fluoroquinolones in young children and voluntarily have avoided them. However in 2002, more than 182,000 courses of fluoroquinolones were administered to children. Research data is limited but the pediatric safety profile appears to be similar to the adult safety profile. Current indications for fluoroquinolones include complicated urinary tract infections, treatment of opportunistic infections in immunocompromised pat...
Source: PediatricEducation.org - October 5, 2009 Category: Pediatrics Authors: Donna M. D'Alessandro, M.D. Tags: Uncategorized Source Type: info

NIAID To Fund Development Of Emergent BioSolutions' Advanced Anthrax Vaccine CandidateEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Emergent BioSolutions Inc. (NYSE:EBS) announced that it was awarded a cooperative agreement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to further the development of one of Emergent's advanced anthrax vaccine candidates known as dmPA7909. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 2, 2009 Category: Consumer Health News Tags: Bio-terrorism / Terrorism Source Type: news

Unanswered questions and ethical issues concerning US biodefence research [Controversies]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Unanswered questions and ethical issues associated with US biodefence medical research over the past five decades are discussed. Objective scientific standards are essential for making policy decisions that can stand the test of time. For decades, scholars have reported that the human anthrax vaccine field trials conducted in the 1950s by Brachman and his colleagues were single-blind rather than double-blind. Nevertheless, in March 2005, Dr Philip S Brachman reported in a letter to the US Food and Drug Administration that his study had been double-blind. It is here argued that, rather, the field trial of a human anthrax va...
Source: Journal of Medical Ethics - September 30, 2009 Category: Medical Ethics Authors: Schumm, W R, Nazarinia, R R, Bosch, K R Tags: Clinical trials (epidemiology) Controversies Source Type: journals

[Controversies] Unanswered questions and ethical issues concerning US biodefence researchEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Unanswered questions and ethical issues associated with US biodefence medical research over the past five decades are discussed. Objective scientific standards are essential for making policy decisions that can stand the test of time. For decades, scholars have reported that the human anthrax vaccine field trials conducted in the 1950s by Brachman and his colleagues were single-blind rather than double-blind. Nevertheless, in March 2005, Dr Philip S Brachman reported in a letter to the US Food and Drug Administration that his study had been double-blind. It is here argued that, rather, the field trial of a human anthrax va...
Source: Journal of Medical Ethics - September 29, 2009 Category: Medical Ethics Authors: Schumm, W R, Nazarinia, R R, Bosch, K R Tags: Clinical trials (epidemiology) Controversies Source Type: journals

Development of antibodies against anthrose tetrasaccharide for specific detection of B. anthracis spores.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The immunological detection of Bacillus anthracis in various environmental samples and the discrimination from other members of the B. cereus group is not well established yet. To generate specific discriminating antibodies, we immunized rabbits, mice and chicken with inactivated B. anthracis spores and, additionally, rabbits and mice with the tetrasaccharide [beta-Ant-(1-->3)-alpha-L-Rhap-(1-->3)-alpha-L-Rhap-(1-->2)-L-Rhap]. It is a constituent of the exosporium glycoprotein BclA and contains the newly discovered sugar anthrose [2-O-methyl-4-(3-hydroxy-3-methylbutamido)-4,6-dideoxy-beta-D-glucose]. The BclA ...
Source: Clinical and Vaccine Immunology - September 29, 2009 Category: Allergy & Immunology Authors: Kuehn A, Kovác P, Saksena R, Bannert N, Klee SR, Ranisch H, Grunow R Tags: Clin vaccine Immunol Source Type: journals

Military Anthrax Vaccine Mandate is UpheldEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Appeals Court Upholds Dismissal of Lawsuit by Service Members who Question Its Effectiveness (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - September 29, 2009 Category: Consumer Health News Source Type: news

Medical countermeasures to protect humans from anthrax bioterrorism.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article summarizes the most important medical countermeasures that have mostly been developed since the 2001 events, and highlights current problems and possible avenues for future research. PMID: 19781945 [PubMed - as supplied by publisher] (Source: Trends in Microbiology)
Source: Trends in Microbiology - September 22, 2009 Category: Microbiology Authors: Bouzianas DG Tags: Trends Microbiol Source Type: journals

Recombinant Sindbis Virus Vectors Designed to Express Protective Antigen of Bacillus anthracis Protect Animals from Anthrax and Display Synergy with Ciprofloxacin.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Recombinant Sindbis viruses were engineered to express alternative forms of the protective antigen of Bacillus anthracis. The recombinant viruses induced PA-specific IgG and neutralizing antibodies in Swiss Webster mice. Vaccination with the recombinant viruses induced immunity that offered some protection from a lethal Ames spore challenge, and synergized the protective effects of ciprofloxacin. PMID: 19759250 [PubMed - as supplied by publisher] (Source: Clinical and Vaccine Immunology)
Source: Clinical and Vaccine Immunology - September 15, 2009 Category: Allergy & Immunology Authors: Thomas JM, Moen ST, Gnade BT, Vargas-Inchaustegui DA, Foltz SM, Suarez G, Heidner HW, König R, Chopra AK, Peterson JW Tags: Clin vaccine Immunol Source Type: journals

Scientists Move Closer To A Safer Anthrax VaccineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers have identified two small protein fragments that could be developed into an anthrax vaccine that may cause fewer side effects than the current vaccine. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 7, 2009 Category: Science Source Type: news

Scientists Move Closer To A Safer Anthrax VaccineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers at Albert Einstein College of Medicine of Yeshiva University have identified two small protein fragments that could be developed into an anthrax vaccine that may cause fewer side effects than the current vaccine. The research is significant because anthrax is considered a major bioterrorism threat. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 5, 2009 Category: Consumer Health News Tags: Bio-terrorism / Terrorism Source Type: news

Einstein Scientists Move Closer to a Safer Anthrax VaccineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Future Vaccine Could Benefit Military and Others at High Risk ... go to aecom.yu.edu for full story (Source: Einstein News)
Source: Einstein News - September 4, 2009 Category: Universities & Medical Training Source Type: organizations

PharmAthene Presents Data for Valortim Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ANNAPOLIS, Md., Sept. 3 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that data from the Company's third generation... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 4, 2009 Category: Pharmaceuticals Source Type: clinical trials

Einstein scientists move closer to a safer anthrax vaccineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Albert Einstein College of Medicine) Researchers at Albert Einstein College of Medicine of Yeshiva University have identified two small protein fragments that could be developed into an anthrax vaccine that may cause fewer side effects than the current vaccine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 4, 2009 Category: Global & Universal Source Type: news

Identification of Linear Epitopes in Bacillus anthracis Protective Antigen Bound by Neutralizing Antibodies [Biomolecular Networks]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Protective antigen (PA), the binding subunit of anthrax toxin, is the major component in the current anthrax vaccine, but the fine antigenic structure of PA is not well defined. To identify linear neutralizing epitopes of PA, 145 overlapping peptides covering the entire sequence of the protein were synthesized. Six monoclonal antibodies (mAbs) and antisera from mice specific for PA were tested for their reactivity to the peptides by enzyme-linked immunosorbent assays. Three major linear immunodominant B-cell epitopes were mapped to residues Leu156 to Ser170, Val196 to Ile210, and Ser312 to Asn326 of the PA protein. Two mAb...
Source: Journal of Biological Chemistry - September 3, 2009 Category: Chemistry Authors: Abboud, N., De Jesus, M., Nakouzi, A., Cordero, R. J. B., Pujato, M., Fiser, A., Rivera, J., Casadevall, A. Tags: Biomolecular Networks Source Type: journals

RaxibacumabEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bacillus anthracis, the organism that causes anthrax infections, was the first bacterium demonstrated to cause a disease. The use of anthrax as a biological weapon dates back to World War I, when the German army is believed to have injected horses, mules and cattle with anthrax toxin. In 1937 Japan initiated a biological warfare program, and the U.S. and U.K. followed suit half a decade later. The United States' biological weapons program was terminated in 1969, and in 1972 the Biological Weapons and Toxins Convention outlawed the development and stockpiling of biological weapons. Since that time, however, this class of we...
Source: Prous Science - Molecule of the Month - September 1, 2009 Category: Chemistry Source Type: info

Poly-γ-d-glutamic acid and protective antigen conjugate vaccines induce functional antibodies against the protective antigen and capsule of Bacillus anthracis in guinea-pigs and rabbitsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we report that PA[ndash]PGA conjugates induce expressions of anti-PA, anti-PGA and toxin-neutralizing antibodies in guinea-pigs and completely protect guinea-pigs against a 50 × LD50 challenge with fully virulent B. anthracis spores. Polyclonal rabbit antisera produced against either PA or ovalbumin conjugated to a PGA-15mer offer a partial passive protection to guinea-pigs against B. anthracis infection, indicating that anti-PGA antibodies play a protective role. Our results demonstrate that PA[ndash]PGA conjugate vaccines are effective in the guinea-pig model, in addition to the previously reported mouse ...
Source: FEMS Immunology and Medical Microbiology - August 31, 2009 Category: Microbiology Authors: Deog-Yong Lee, Jeong-Hoon Chun, Hyun-Joon Ha, Jungchan Park, Bong-Su Kim, Hee-Bok Oh, Gi-Eun Rhie Source Type: journals

Reproductive toxicity of BioThrax® in rabbitsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: AVA directly, or indirectly through the production of anti-PA IgG, did not appear to have an adverse effect on the pregnant females or their offspring, as measured by mating and fertility indices, natural delivery observations, clinical signs, gross lesions, in utero growth and survival, morphological development, or kit viability. Birth Defects Res (Part B), 2009. © 2009 Wiley-Liss, Inc. (Source: Birth Defects Research Part B: Developmental and Reproductive Toxicology)
Source: Birth Defects Research Part B: Developmental and Reproductive Toxicology - August 28, 2009 Category: Perinatology & Neonatology Authors: Cynthia Franco, Elise Lewis, Sandra Morseth, Louise Simon, A. Thomas Waytes Source Type: journals

Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007 [Vaccine 2009;27:290-297].Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19716457 [PubMed - as supplied by publisher] (Source: Vaccine)
Source: Vaccine - August 25, 2009 Category: Allergy & Immunology Authors: Niu M, Ball R Tags: vaccine Source Type: journals

Bioterrorism and Infectious AgentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A New Dilemma for the 21st Century series: Emerging Infectious Diseases of the 21st Century This volume in the series Emerging Infectious Diseases of the 21st Century provides the most up-to-date and comprehensive information available on bioterrorism agents such as:Anthrax, smallpox, plague, and SARS Vaccine development New anti-viral drug development Treatment and protection Threat analysis and response Biological and chemical agents Compiled by two of the leading ... (Source: Springer Medicine titles)
Source: Springer Medicine titles - August 20, 2009 Category: Databases & Libraries Tags: Infectious Diseases Source Type: organizations

Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Gulf War Syndrome is a multi-system disorder afflicting many veterans of Western armies in the 1990-1991 Gulf War. A number of those afflicted may show neurological deficits including various cognitive dysfunctions and motor neuron disease, the latter expression virtually indistinguishable from classical amyotrophic lateral sclerosis (ALS) except for the age of onset. This ALS "cluster" represents the second such ALS cluster described in the literature to date. Possible causes of GWS include several of the adjuvants in the anthrax vaccine and others. The most likely culprit appears to be aluminum hydroxide. In an initi...
Source: Journal of Inorganic Biochemistry - August 19, 2009 Category: Biochemistry Authors: Shaw CA, Petrik MS Tags: J Inorg Biochem Source Type: journals

Analysis of the Fc{gamma} Receptor-Dependent Component of Neutralization Measured by Anthrax Toxin Neutralization Assays.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we investigated the magnitude and molecular nature of Fcgamma receptor-dependent toxin neutralization observed in commonly used forms of the anthrax toxin neutralization assay. Significantly more Fcgamma receptor-dependent neutralization was observed in the J774A.1 cell-based assay as compared to the RAW 264.7 cell-based assay, a finding that could be due to larger numbers of Fcgamma receptors that we found on J774A.1 cells using flow cytometry. Thus, the extent to which Fcgamma receptor-dependent neutralization contributes to the total neutralization measured by the assay depends on the specific cell type u...
Source: Clinical and Vaccine Immunology - August 4, 2009 Category: Allergy & Immunology Authors: Verma A, Ngundi MM, Meade BD, De Pascalis R, Elkins KL, Burns DL Tags: Clin vaccine Immunol Source Type: journals

Novel and Unique Diagnostic Biomarkers for Bacillus anthracis Infection.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Search of bacterial-specific biomarkers in peripheral blood, following infection with Bacillus anthracis was carried out in rabbits using a battery of specific antibodies generated by DNA vaccination against 10 pre-selected highly immunogenic bacterial antigens which were identified previously by a genomic/proteomic/serologic screen of the B. anthracis secretome. Detection of infection biomarkers in the circulation of infected rabbits could be achieved only after removal of highly abundant serum proteins by chromatography using a random-ligand affinity column. Besides the toxin component Protective Antigen (PA), three ...
Source: Applied and Environmental Microbiology - July 30, 2009 Category: Microbiology Authors: Sela-Abramovich S, Chitlaru T, Gat O, Grosfeld H, Cohen O, Shafferman A Tags: Appl Environ Microbiol Source Type: journals

Protection against anthrax and plague by a combined vaccine in mice and rabbits.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, the authors have investigated the antibody responses and the protective efficacy when the antigens were administered separately or in combination intramuscularly formulation adsorbed to an aluminum hydroxide adjuvant. Results show that immunized rF1+rV and rPA antigen together was as effective as separately for induction of serological antibody response, and these titers were maintained for over 1 year in mice. An isotype analysis of the serum indicates that the co-administration of these antigens did not influence the antigen-specific IgG1/IgG2a ratio which was consistent with a Th2 bias. Furthermore, the c...
Source: Vaccine - July 23, 2009 Category: Allergy & Immunology Authors: Ren J, Dong D, Zhang J, Liu S, Li B, Fu L, Xu J, Yu C, Hou L, Li J, Chen W Tags: vaccine Source Type: journals

Gamma-phage lysin PlyG sequence-based synthetic peptides coupled with Qdot-nanocrystals are useful for developing detection methods for Bacillus anthracis by using its surrogates, B. anthracis-Sterne and B. cereus-4342Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Overall, these studies illustrate that the short 10-amino acid sequence 'LKMTADFILQ' in fact is a stand-alone bacterial cell wall-binding motif of PlyG. In principle, synthetic peptides PlyG-P1, PlyG-P3 and PlyG-P5, especially PlyG-P3 coupled with Qdot-nanocrystals are useful as high-sensitivity bio-probes in developing detection technologies for B. anthracis. (Source: BMC Biotechnology - Latest articles)
Source: BMC Biotechnology - Latest articles - July 21, 2009 Category: Biotechnology Authors: Shilpakala SainathraoKetha Krishna MohanChintamani Atreya Source Type: journals

PharmAthene's 2nd Generation RPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company's proposed development plan for SparVax(TM), PharmAthene's next generation recombinant protective antigen (rPA) anthrax vaccine. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 10, 2009 Category: Consumer Health News Tags: Bio-terrorism / Terrorism Source Type: news

PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax™, Completes FDA Regulatory Strategy ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company's proposed development plan for SparVax™, PharmAthene's next generation recombinant protective antigen (rPA) anthrax vaccine. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - July 9, 2009 Category: Pharmaceuticals Source Type: news

Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, libraries of polyclonally expanded naive T cells were used to determine frequency and antigen dose–response of human naive CD4+ T cells specific for a variety of antigens and to isolate antigen-specific T cell clones. In the naive repertoire, T cells specific for primary antigens, such as KLH and Bacillus anthracis protective antigen, and for recall antigens, such as tetanus toxoid, cytomegalovirus, and Mycobacterium tuberculosis purified protein derivative, were detected at frequencies ranging from 5 to 170 cells per 106 naive T cells. Antigen concentrations required for half-maximal response (EC50) v...
Source: The Journal of Experimental Medicine - July 5, 2009 Category: Internal Medicine Authors: Geiger, R., Duhen, T., Lanzavecchia, A., Sallusto, F. Tags: Brief Definitive Reports Source Type: journals

Namibia: Northern Anthrax Fears TamedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The risk of an anthrax outbreak in the flood stricken areas in the north motivated the Veterinary Association of Namibia to donate vaccines to the Directorate of Veterinary Services. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 3, 2009 Category: African Health Source Type: news

Emergent BioSolutions Meets With FDA To Review Regulatory Strategy For Recombinant Anthrax VaccineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Emergent BioSolutions Inc. (NYSE:EBS) announced that it has met with the U.S. Food and Drug Administration (FDA) to review Emergent's regulatory strategy for the development of its recombinant anthrax (rPA) vaccine. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 14, 2009 Category: Consumer Health News Tags: Bio-terrorism / Terrorism Source Type: news

Emergent BioSolutions Receives FDA Approval Extending Shelf Life Of BioThrax (Anthrax Vaccine Adsorbed) To 4 YearsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Emergent BioSolutions Inc. (NYSE:EBS) announced that its flagship product, BioThrax® (Anthrax Vaccine Adsorbed), has been granted a shelf life extension from 3 to 4 years by the U.S. Food and Drug Administration (FDA). (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 12, 2009 Category: Consumer Health News Tags: Bio-terrorism / Terrorism Source Type: news

Emergent BioSolutions Receives FDA Approval Extending Shelf Life of BioThrax (Anthrax Vaccine Adsorbed) to 4 YearsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ROCKVILLE, Md.--(BUSINESS WIRE)--Jun 10, 2009 - Emergent BioSolutions Inc. (NYSE:EBS) announced today that its flagship product, BioThrax (Anthrax Vaccine Adsorbed), has been granted a shelf life extension from 3 to 4 years by the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 11, 2009 Category: Drugs & Pharmacology Source Type: news

AnthraxEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
— Comprehensive overview covers symptoms, vaccine, risks of this deadly bacterial disease. Sponsored by:Chemotherapy.com - http://www.chemotherapy.com (Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - June 9, 2009 Category: Consumer Health News Source Type: news

Secondary cell wall polysaccharides of Bacillus anthracis are antigens that contain specific epitopes which cross-react with three pathogenic Bacillus cereus strains that caused severe disease, and other epitopes common to all the Bacillus cereus strains testedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The immunoreactivities of hydrogen fluoride (HF)-released cell wall polysaccharides (HF-PSs) from selected Bacillus anthracis and Bacillus cereus strains were compared using antisera against live and killed B. anthracis spores. These antisera bound to the HF-PSs from B. anthracis and from three clinical B. cereus isolates (G9241, 03BB87, and 03BB102) obtained from cases of severe or fatal human pneumonia but did not bind to the HF-PSs from the closely related B. cereus ATCC 10987 or from B. cereus type strain ATCC 14579. Antiserum against a keyhole limpet hemocyanin conjugate of the B. anthracis HF-PS (HF-PS-KLH) also boun...
Source: Glycobiology - May 14, 2009 Category: Biology Authors: Leoff, C., Saile, E., Rauvolfova, J., Quinn, C. P, Hoffmaster, A. R, Zhong, W., Mehta, A. S, Boons, G.-J., Carlson, R. W, Kannenberg, E. L Tags: Original Article Source Type: journals

Emergent BioSolutions Launches BioThrax.com, An Educational Website About BioThrax (Anthrax Vaccine Adsorbed) And Anthrax DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Emergent BioSolutions Inc. (NYSE:EBS) announced the launch of http://www.biothrax.com, a website that provides information about BioThrax® (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration (FDA) for the prevention of anthrax infection. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 11, 2009 Category: Consumer Health News Tags: Bio-terrorism / Terrorism Source Type: news

PharmAthene Presents Data For SparVax(TM), A Novel Vaccine For The Prevention And Treatment Of Anthrax InfectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced that results from a second Phase II study of SparVax(TM) were presented yesterday at the 12th Annual Conference on Vaccine Research, being held in Baltimore, MD, April 27-29, 2009. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 29, 2009 Category: Consumer Health News Tags: Infectious Diseases / Bacteria / Viruses Source Type: news

PharmAthene Presents Data for SparVax, a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine ResearchEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ANNAPOLIS, Md., April 28, 2009 /PRNewswire/ -- PharmAthene, Inc. , a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a second Phase II study of SparVax(TM) were... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 28, 2009 Category: Pharmaceuticals Source Type: clinical trials

HHS Extends Deadline For Bidders In Competitive Range For Recombinant Anthrax Vaccine Contract To Submit Development Plan To FDA For ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Department of Health and Human Services (HHS) issued an additional amendment to its request for proposal for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile. (Source: Bio-terrorism / Terrorism News From Medical News Today)
Source: Bio-terrorism / Terrorism News From Medical News Today - April 24, 2009 Category: Global & Universal Tags: Immune System / vaccines Source Type: news

HHS Requires Bidders In Competitive Range For Recombinant Anthrax Vaccine (rPA) Contract To Submit Development Plan To FDA For ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Emergent BioSolutions Inc. (NYSE:EBS) announced that late on April 15th, HHS requested that each bidder in the competitive range for the rPA contract submit its product development plans to FDA for review in advance of an award. Emergent had already requested and is presently scheduling a meeting with the FDA as part of its pre-award activity. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 19, 2009 Category: Consumer Health News Tags: Immune System / vaccines Source Type: news

Existing antibacterial vaccinesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article will review the currently approved antibacterial vaccines, which are vaccines for pertussis, tetanus, diphtheria, meningococcus, pneumococcus, Haemophilus influenza, cholera, typhoid, and anthrax. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - March 25, 2009 Category: Dermatology Authors: Natalia Mendoza, Parisa Ravanfar, Anita Satyaprakah, Sivaprabha Pillai, Rosella Creed Tags: vaccines in Dermatology Source Type: journals

Nanotechnology May Aid in Earlier Anthrax DetectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A new test utilizing nanotechnology may be able to detect anthrax infection earlier than existing methods, according to a U.S. Food and Drug Administration announcement of research published in the March Clinical and Vaccine Immunology. (Source: Modern Medicine)
Source: Modern Medicine - March 23, 2009 Category: Journals (General) Source Type: info

New Generation Oral Vaccine Uses Dairy Probiotics To Protect Against DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Instead of a dreaded injection with a needle, someday getting vaccinated against disease may be as pleasant as drinking a yogurt smoothie. A researcher from the Northwestern University Feinberg School of Medicine has developed a new oral vaccine using probiotics, the healthy bacteria that are found in dairy products like yogurt and cheese. He has successfully used the approach in a preclinical study to create immunity to anthrax exposure. (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - March 19, 2009 Category: Cancer & Oncology Tags: Immune System / vaccines Source Type: news

Goodbye Needle, Hello Smoothie: New Generation Oral Vaccine Uses Dairy Probiotics To Protect Against DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Instead of a shot, someday getting vaccinated against disease may be as pleasant as drinking a yogurt smoothie. A researcher has developed a new oral vaccine using probiotics, the healthy bacteria in dairy products. He has successfully used the vaccine to create immunity to anthrax. He also is developing a breast cancer vaccine using probiotics and vaccines for various infectious diseases. Delivering the vaccine to the gut produces the most robust immune response. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 18, 2009 Category: Science Source Type: news

Efficacy of recombinant anthrax vaccine against Bacillus anthracis aerosol spore challenge: Preclinical evaluation in rabbits and Rhesus monkeys.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This report describes the immunogenicity and protective efficacy of Escherichia coli-expressed recombinant protective antigen (rPA) in New Zealand White rabbits and Rhesus Macaques against an aerosol challenge with Bacillus anthracis spores (IVRI strain, tox+cap+). A dose-ranging study was performed in which it became evident that the level of anti-PA IgG and toxin-neutralizing antibody titer was directly proportional to the dose of rPA administered. However, the onset time of primary and secondary immune response was not dependent on the dosage. Revaccination of primed animals with the same threshold dose yielded a robust...
Source: Biotechnology Journal - March 18, 2009 Category: Biotechnology Authors: Chawla A, Midha S, Bhatnagar R Tags: Biotechnol J Source Type: journals

Passport Health of Massachusetts: Passport Health of Massachusetts, Sole Non-Military Source for Anthrax Inoculations, Warns International Travelers, "No Place Is Completely Safe From Anthrax Attacks"Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
WOBURN, MA (MARKET WIRE) Passport Health of Massachusetts (http://www.passporthealthma.com), specialists in vaccinations against dread diseases faced by international travelers, is the sole source private provider of the Anthrax vaccine in the United States. (Source: Market Wire - Pharmaceuticals and Biotech)
Source: Market Wire - Pharmaceuticals and Biotech - March 17, 2009 Category: Pharmaceuticals Tags: Government Pharmaceuticals and Biotech Medical and Healthcare Source Type: news